MAY 28, 2020 5:20 AM PDT

The Oncogenic Hazard of a Potential Alzheimer's Treatment

WRITTEN BY: Jasper Cantrell

Breast cancer remains one of the most common cancers around the world. Triple-Negative Breast Cancer (TNBC) is a sub-type that has been a challenge to treat. TNBC does not have any easily targetable attributes, with chemotherapy or radiotherapy being the only treatment option. This is not ideal, considering TNBC tends to develop chemoresistance. The search for a new treatment along for TNBC led a group from Argentina to examine a protein they had been working on and its possible role in breast cancer.

The protein in question is humanin (HN). Humanin is a small peptide that originates from the mitochondria. It, and six other small HN-like peptides, are some of the rare mitochondrially encoded genes. While there are more in the nuclear genome, only the mitochondrial variants are expressed to any significant level. HN is currently a front-line target for possible treatment of Alzheimer’s, diabetes, and other diseases due to its cytoprotective abilities. Unfortunately, HN has also been a known oncogene for decades. There has been very little research for HN’s connection to cancer, with recent work showing high expression levels in gastric, bladder, and pituitary cancers.

Normally, HN regulates mitochondrial based apoptotic pathways by interacting with a family of proteins called the B-cell lymphoma 2 (Bcl-2) and inhibiting the release of apoptotic signaling factors. It has also been linked to a few cellular receptors known to activate pathways involved in cellular proliferation, such as the RAS/MAPK and PI3K pathways. Both of these give credence to its cytoprotective properties, as well as its pro-tumor properties.

The team began their experiments by examining HN levels in human and mouse breast tissue. HN was present in all tissues tested but was mildly overexpressed in TNBC tissue. Using a mouse TNBC cell line, they examined HN’s effect on cellular growth in a cytotoxic environment, as well as in the presence of a chemotherapy drug doxorubicin (DOXO). The addition of HN to the cytotoxic environment brought growth levels back to what they would be in a normal environment. HN addition to DOXO treated cells inhibited the growth impairment normally seen. Silencing the HN gene in the cells concurrently led to an increase in DOXO’s anti-tumor effects. A mouse model using the same TNBC cell line to induce tumor formation confirmed this interaction, with DOXO treated mice showing a tumor growth impairment that is abrogated when HN was added alongside DOXO. HN alone actually promoted tumor growth, and metastasis as tumors spread to the lungs of the mice.

The team concluded, “Our study shows that HN facilitates tumor progression and chemo-resistance in an experimental model of breast cancer.” Considering HN is a target for the treatment of several diseases, its pro-tumor effects need to be studied in far more detail. The group points out some conflicting work concerning glioblastomas. However, different methods make it a challenge to compare the two. Regardless, before humanin can be used as a treatment, its role as an oncogene must be studied further before it can move into any clinical phases.

Sources: Nature, Catalyst University
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUN 15, 2020
Cancer
New treatment for malignant pleural mesothelioma
JUN 15, 2020
New treatment for malignant pleural mesothelioma
New research reported during a virtual presentation of the Society of Interventional Radiology's 2020 Annual Scienti ...
JUL 02, 2020
Cancer
Common hypertension medicine may reduce risk of colorectal cancer
JUL 02, 2020
Common hypertension medicine may reduce risk of colorectal cancer
There is hope that ACE inhibitors and ARBs, medications that are commonly prescribed for high blood pressure, may be hel ...
JUL 13, 2020
Cancer
Workers in Transportation Might be More at Risk for Cancer
JUL 13, 2020
Workers in Transportation Might be More at Risk for Cancer
Road transportation workers are essential employees in any country. They represent truck, bus, taxi, and other such driv ...
JUL 10, 2020
Cancer
Why do black men suffer disproportionately from prostate cancer?
JUL 10, 2020
Why do black men suffer disproportionately from prostate cancer?
Cancer disparities by race are widely acknowledged. One in every six black men will be diagnosed with prostate cancer in ...
JUL 13, 2020
Cancer
Breast cancer patients are 60% more likely to die of cancer after surviving a heart attack
JUL 13, 2020
Breast cancer patients are 60% more likely to die of cancer after surviving a heart attack
Unwelcome news from researchers at NYU Grossman School of Medicine suggests that breast cancer patients are 60% more lik ...
JUL 25, 2020
Cancer
Researchers use algorithm to develop comprehensive list of pediatric cancer-causing mutations
JUL 25, 2020
Researchers use algorithm to develop comprehensive list of pediatric cancer-causing mutations
A breakthrough study published recently in Science Advances reports the creation of a list of mutations in the noncoding ...
Loading Comments...